This book covers a wide range of novel biochemical targets that appear to be the best leads in terms of designing novel targets for anticancer drug design. New Molecular Targets for Cancer Chemotherapy is a unique, multi-disciplinary effort, with internationally respected authors from the fields of growth factor-receptor interaction, phosphoinositide and phospholipase signal transduction, and DNA-drug binding interactions. The science is placed in clinical context and illustrations explain how clinicians can incorporate a mechanistic, pharmacodynamic approach into early clinical trial design.
The Potential for Molecular Oncology to Define New Drug Targets (P. Workman). An Overview of the Regulation of Phospholipase-Linked Cell Signaling (M.J.O. Wakelam). Growth Factor Receptors as Targets (F.J. Lofts and W.J. Gullick). Protein Tyrosine Kinase Inhibitors (A. Levitzkie). Inhibitors of myo-Inositol Signaling (G. Powis and A. Kozikowski). The Properties of ras p21 and Its Potential Value as a Therapeutic Target (R.J.A. Grand). Protein Kinase C (A. Basu and J.S. Lazo). Apoptosis as a Target for Cancer Chemotherapy (A. Eastman and M.A. Barry). DNA Sequences as Targets for New Anticancer Agents (S. Neidle and D.E. Thurston). P-Glycoprotein, a Transporter with Allosterically Coupled Drug--Acceptor Sites as a Target for Rational Drug-Design (D.R. Ferry and D.J. Kerr). The Clinical Evaluation of Novel Chemotherapeutic Agents (C.J. Poole and D.J. Kerr). Index.